NDA 018938 · J Molner
Ddavp
Desmopressin Acetate · Injection
Priority reviewLast checked: Nov 20, 2026Latest source record: Jul 21, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
Mar 30, 1984
Approved uses
1
Original approval plus efficacy supplements
Registered trials
99
23 Phase 3, 8 recruiting
FAERS reports
3,313
2,397 serious, 238 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPONATREMIA Desmopressin acetate can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death [see Warnings and Precautions (5.1) ]. Desmopressin acetate is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids [see Contraindications (4) and Warnings and Precautions (5.1) ]. Ensure the serum sodium concentration is normal before starting or resuming desmopressin acetate. Measure serum sodium within 7 days and approximately 1 month after initiating therapy, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia [see Dosage...
What it is approved for
From the label in effect Oct 24, 2025.
Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 ) Limitations of Use Desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. ( 1.3 ) von Willebrand’s disease (severe Type I) - not indicated for the treatment of patients with severe Type I von Willebrand’s disease and when there is evidence of an abnormal molecular form of factor VIII antigen. ( 1.3 ) 1.1 Central Diabetes Insipidus Desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Limitations of Use: Desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. 1.2 Hemophilia A Desmopressin acetate injection is indicated for patients with hemophilia A with factor VIII coagulant activity levels...
Mechanism: Desmopressin acetate increases plasma levels of factor VIII activity in patients with hemophilia and von Willebrand’s disease Type I. The antidiuretic effects of desmopressin acetate are mediated by stimulation of vasopressin 2 (V2) receptors, thereby increasing water re-absorption in the kidney, and hence reducing urine production. Desmopressin acetate is a replacement hormone for antidiuretic hormone in the treatment of central diabetes insipidus. The change in structure of arginine vasopressin to desmopressin acetate resulted in increased duration of action and a decreased vasopressor...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 30, 1984 Original approval · Type 3 - New Dosage Form · priority review
2 products under this application
- DDAVP · DESMOPRESSIN ACETATE 0.004MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- DDAVP · DESMOPRESSIN ACETATE 0.015MG/ML · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Desmopressin" as an intervention, any sponsor and status, largest first.
- A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal EnuresisPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00245479 · 802 participants · Start Apr 2002 · Primary completion Sep 2005
Drug: Primary nocturnal enuresis · For: Nocturnal Enuresis
Sites: Paris, France
- Efficacy and Safety of Desmopressin Melt for the Treatment of NocturiaPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00477490 · 799 participants · Start May 2007 · Primary completion Feb 2008
Drug: desmopressin acetate; Placebo · For: Nocturia
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 80 sites in all
- An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in AdultsPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00615836 · 554 participants · Start Dec 2007 · Primary completion May 2010
Drug: Desmopressin Melt · For: Nocturia
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Anaheim, California · 73 sites in all
- Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese SubjectsPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT03051009 · 503 participants · Start Jan 11, 2017 · Primary completion Sep 11, 2018
Drug: Desmopressin ODT 25 μg; Desmopressin ODT 50 μg · For: Nocturia
Sites: Tokyo, Japan
- Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of DesmopressinPivotal-lookingRecruiting
Medical University of BialystokAcademic, hospital or other
NCT05467033 · 424 participants (planned) · Start Sep 1, 2022 · Primary completion Aug 31, 2026
Drug: Desmopressin; intravenous infusion NaCl · For: Kidney Biopsy
Sites: Bialystok, Poland
- Study on Chinese and Western Medicine in MNE ChildrenPivotal-lookingCompleted
Children's Hospital of Fudan UniversityAcademic, hospital or other
NCT03733873 · 400 participants · Start Sep 1, 2018 · Primary completion Jan 30, 2020
Drug: Desmopressin; Suoquan · For: Monosymptomatic Nocturnal Enuresis
Sites: Shanghai, China
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal EnuresisPivotal-lookingCompleted
Menoufia UniversityAcademic, hospital or other
NCT06771128 · 398 participants · Start Nov 1, 2024 · Primary completion Dec 1, 2025
Drug: Ginkgo Biloba oral tablet; Desmopressin Acetate 0.2 mg Tablets and 2 more · For: Nocturnal Enuresis in Children; Desmopressin; Monosymptomatic Nocturnal Enuresis
Sites: Shebin El-Kom, Egypt
- Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male PatientsPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT01262456 · 395 participants · Start Feb 2011 · Primary completion Jan 2012
Drug: Desmopressin; Placebo · For: Nocturia
Sites: Anniston, Alabama; Huntsville, Alabama; Scottsdale, Arizona · 56 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hyponatraemia339
- drug ineffective221
- headache191
- nausea181
- fatigue145
- off label use143
- vomiting138
- dizziness117
- diarrhoea110
- pain105
- asthenia98
- malaise87
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 80 |
| 2005 | 63 |
| 2006 | 75 |
| 2007 | 48 |
| 2008 | 143 |
| 2009 | 147 |
| 2010 | 141 |
| 2011 | 138 |
| 2012 | 167 |
| 2013 | 100 |
| 2014 | 135 |
| 2015 | 133 |
| 2016 | 183 |
| 2017 | 173 |
| 2018 | 166 |
| 2019 | 144 |
| 2020 | 152 |
| 2021 | 172 |
| 2022 | 196 |
| 2023 | 189 |
| 2024 | 255 |
| 2025 | 195 |
| 2026 | 118 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ddavp* (Desmopressin Acetate)
2024 spending
$348K
Beneficiaries
52
297 claims
Per beneficiary
$6,696
$10.04 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $772,773 |
| 2021 | $599,706 |
| 2022 | $518,805 |
| 2023 | $420,012 |
| 2024 | $348,215 |
Part B: Ddavp* (Desmopressin Acetate*) · HCPCS J2597
2024 spending
$356K
Beneficiaries
2,151
2,468 claims
Per beneficiary
$165
2024 ASP limit $5.90 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $535,096 |
| 2021 | $573,116 |
| 2022 | $461,489 |
| 2023 | $388,512 |
| 2024 | $355,880 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Central diabetes insipidus (vasopressin deficiency) after surgery for pituitary tumours: a systematic review and meta-analysis.
Fountas A, Coulden A, Fernández-García S, et al. · Eur J Endocrinol 2024 · Systematic Review, Meta-Analysis
- DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis.
Laan S, Del Castillo Alferez J, Cannegieter S, et al. · Blood 2025 · Systematic Review, Meta-Analysis
- Desamino-D-arginine-vasopressin (DDAVP) in Alzheimer's disease.
Peabody CA, Davies H, Berger PA, et al. · Neurobiol Aging 1986 · Clinical Trial, Comparative Study
- Desmopressin for treating nocturia in men.
Han J, Jung JH, Bakker CJ, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S.
- Desmopressin for treating nocturia in men.
Han J, Jung JH, Bakker CJ, et al. · BJU Int 2018 · Meta-Analysis, Systematic Review
- Vasopressin analogue DDAVP in diabetes insipidus: clinical and laboratory studies.
Edwards CR, Kitau MJ, Chard T, et al. · Br Med J 1973 · Clinical Trial
Sponsor: J Molner
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.